Item 8.01 Other Events

On February 16, 2021, Teligent, Inc. (the "Company") filed supplement no. 1 ("Supplement No. 1") to the prospectus supplement dated January 28, 2021 (the "Prospectus Supplement") relating to its previously disclosed At Market Issuance Sales Agreement (the "Sales Agreement"), dated as of January 27, 2021, by and among the Company and B. Riley Securities, Inc., as agent ("B. Riley Securities"), to increase, pursuant to the terms of the Sales Agreement, from $22,619,204 to $50,000,000, the aggregate amount of shares of the Company's common stock, par value $0.01 per share (the "Shares"), that may be sold through or to B. Riley Securities under the Sales Agreement.

As previously reported, under the Sales Agreement, the Company may sell Shares from time to time through or to B. Riley Securities pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-224188) that became effective on May 18, 2018, supplemented by the Prospectus Supplement. In accordance with the terms of the Sales Agreement, sales of Shares under the Prospectus Supplement and the accompanying base prospectus may be made by any method deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act.

The Company filed Supplement No. 1 in order to increase the aggregate size of the offering to $50,000,000, as a result of an increase in the Company's public float since the date of the Prospectus Supplement. Prior to the start of trading on February 16, 2021, $18,533,157 of Shares had been sold under the Prospectus Supplement (including sales pending ordinary settlement under the Sales Agreement), and, following the filing of Supplement No. 1, an aggregate of up to $31,466,843 of additional Shares may be sold.

A copy of the opinion of K&L Gates LLP relating to the legality of the issuance and sale of the Shares is attached as Exhibit 5.1 hereto.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any offer, solicitation or sale of the Shares in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.



Exhibit No.   Exhibit Description
    5.1         Opinion of K&L Gates LLP
   23.1         Consent of K&L Gates LLP (included in Exhibit 5.1)

© Edgar Online, source Glimpses